These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29316030)

  • 1. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.
    Falade-Nwulia O; Sulkowski MS; Merkow A; Latkin C; Mehta SH
    J Viral Hepat; 2018 Mar; 25(3):220-227. PubMed ID: 29316030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
    Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
    Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
    AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.
    Smit C; Boyd A; Rijnders BJA; van de Laar TJW; Leyten EM; Bierman WF; Brinkman K; Claassen MAA; den Hollander J; Boerekamps A; Newsum AM; Schinkel J; Prins M; Arends JE; Op de Coul ELM; van der Valk M; Reiss P;
    Lancet HIV; 2021 Feb; 8(2):e96-e105. PubMed ID: 33357835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV.
    Cheng CY; Ku SY; Lin YC; Chen CP; Cheng SH; Lin IF
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C reinfection with protease inhibitor-resistant hepatitis C virus in an HIV-coinfected MSM.
    Yilmaz GR; Boesecke C; Schwarze-Zander C; Rockstroh JK
    Liver Int; 2020 Jan; 40(1):47-50. PubMed ID: 31612570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
    Muller A; Vlahov D; Akiyama MJ; Kurth A
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
    Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
    Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.
    Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS
    Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
    Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
    J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis.
    Martin NK; Jansen K; An der Heiden M; Boesecke C; Boyd A; Schewe K; Baumgarten A; Lutz T; Christensen S; Thielen A; Mauss S; Rockstroh JK; Skaathun B; Ingiliz P
    J Infect Dis; 2019 Oct; 220(10):1635-1644. PubMed ID: 31301142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
    PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
    J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.